NASDAQ:SXTP 60 Degrees Pharmaceuticals (SXTP) Stock Price, News & Analysis $1.08 -0.05 (-4.42%) As of 03:56 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsSEC Filings About 60 Degrees Pharmaceuticals Stock (NASDAQ:SXTP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SXTP alerts:Sign Up Key Stats Today's Range$1.01▼$1.1650-Day Range$1.08▼$1.7852-Week Range$1.01▼$8.62Volume96,933 shsAverage Volume1.78 million shsMarket Capitalization$3.80 millionP/E RatioN/ADividend YieldN/APrice Target$13.85Consensus RatingHold Company Overview 60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia. Read More 60 Degrees Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreSXTP MarketRank™: 60 Degrees Pharmaceuticals scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus Rating60 Degrees Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.Upside Potential60 Degrees Pharmaceuticals has a consensus price target of $13.85, representing about 1,182.4% upside from its current price of $1.08.Amount of Analyst Coverage60 Degrees Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about 60 Degrees Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for 60 Degrees Pharmaceuticals are expected to grow in the coming year, from ($3.31) to ($2.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 60 Degrees Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 60 Degrees Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about 60 Degrees Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.02% of the float of 60 Degrees Pharmaceuticals has been sold short.Short Interest Ratio / Days to Cover60 Degrees Pharmaceuticals has a short interest ratio ("days to cover") of 3.49, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 60 Degrees Pharmaceuticals has recently increased by 34.79%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield60 Degrees Pharmaceuticals does not currently pay a dividend.Dividend Growth60 Degrees Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.57 News Sentiment60 Degrees Pharmaceuticals has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for 60 Degrees Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest5 people have searched for SXTP on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership3.0 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $10,143.00 in company stock, which represents 0.2668% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, 60 Degrees Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,143.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders1.68% of the stock of 60 Degrees Pharmaceuticals is held by insiders.Percentage Held by Institutions7.96% of the stock of 60 Degrees Pharmaceuticals is held by institutions.Read more about 60 Degrees Pharmaceuticals' insider trading history. Receive SXTP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 60 Degrees Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SXTP Stock News HeadlinesWhat is HC Wainwright's Forecast for SXTP Q3 Earnings?August 21, 2026 | americanbankingnews.com60 Degrees Pharmaceuticals Announces Second Quarter 2026 ResultsAugust 14, 2026 | globenewswire.comIt’s not about GreenlandThe petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then, China has cut its Treasury holdings by 45% from their peak, and BRICS nations offloaded $47 billion of American debt in a single month. The Trump administration has responded with a $12 billion critical minerals stockpile called Project Vault, equity stakes in miners like MP Materials and Lithium Americas, and a push to secure resources from Greenland to Ukraine. Porter Stansberry lays out the full story in a new documentary, including five companies positioned at the chokepoints of what he calls Trump's New Dollar.August 26 at 1:00 AM | Porter & Company (Ad)60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq RulesJuly 30, 2026 | globenewswire.com60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026July 29, 2026 | globenewswire.com60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne DiseasesJuly 8, 2026 | globenewswire.com60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis ...July 1, 2026 | markets.businessinsider.com60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe FatigueJuly 1, 2026 | globenewswire.comSee More Headlines SXTP Stock Analysis - Frequently Asked Questions How have SXTP shares performed this year? 60 Degrees Pharmaceuticals' stock was trading at $2.0332 at the start of the year. Since then, SXTP stock has decreased by 46.9% and is now trading at $1.08. How were 60 Degrees Pharmaceuticals' earnings last quarter? 60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) announced its quarterly earnings data on Friday, August, 14th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.16. The firm earned $0.21 million during the quarter, compared to analyst estimates of $0.21 million. When did 60 Degrees Pharmaceuticals' stock split? Shares of 60 Degrees Pharmaceuticals reverse split on Tuesday, January 20th 2026.A 1-4 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 19th 2026. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. When did 60 Degrees Pharmaceuticals IPO? 60 Degrees Pharmaceuticals (SXTP) raised $7 million in an initial public offering on Wednesday, July 12th 2023. The company issued 1,400,000 shares at $5.30 per share. WallachBeth Capital LLC served as the underwriter for the IPO. How do I buy shares of 60 Degrees Pharmaceuticals? Shares of SXTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 60 Degrees Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that 60 Degrees Pharmaceuticals investors own include Recursion Pharmaceuticals (RXRX), Editas Medicine (EDIT), Pacific Biosciences of California (PACB), Tilray Brands (TLRY), Akanda (AKAN), Better Therapeutics (BTTX) and Honeywell International (HON). Company Calendar Last Earnings8/14/2026Today8/26/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 SXTP's financial health is in the Yellow zone, according to TradeSmith. SXTP has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SXTP CIK1946563 Web60degreespharma.com Phone202-327-5422FaxN/AEmployees3Year Founded2010Price Target and Rating Average Price Target for 60 Degrees Pharmaceuticals$13.85 High Price Target$24.00 Low Price Target$3.70 Potential Upside/Downside+1,182.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($4.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.36 million Net Margins-650.21% Pretax Margin-650.62% Return on EquityN/A Return on Assets-136.81% Debt Debt-to-Equity RatioN/A Current Ratio2.32 Quick Ratio1.78 Sales & Book Value Annual Sales$1.41 million Price / Sales2.70 Cash FlowN/A Price / Cash FlowN/A Book Value($2.00) per share Price / Book-0.54Miscellaneous Outstanding Shares3,520,000Free Float3,458,000Market Cap$3.80 million OptionableNot Optionable Beta2.54 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:SXTP) was last updated on 8/26/2026 by MarketBeat.com Staff. From Our PartnersBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredThe Rumors About Elon’s Next Move Are Spreading FastRumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredTrump’s new dollar decreeThe last time America reset its money, it minted 1,300 new millionaires a day. Porter Stansberry believes Exec...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
